1. Azacitidine‐associated haemorrhagic enteritis in a case of myelodysplastic syndrome: A case report
- Author
-
Miki Umeda, Hisashi Tsutsumi, Wataru Shinomiya, Hiroko Hidai, Hideki Akiyama, Yoshiaki Shibata, Reina Saga, Takeshi Hagino, Sayuri Motomura, and Miwa Kurimoto
- Subjects
Pharmacology ,medicine.medical_specialty ,Intestinal ulcers ,business.industry ,Azacitidine ,Case description ,030226 pharmacology & pharmacy ,Gastroenterology ,stomatognathic diseases ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,heterocyclic compounds ,Pharmacology (medical) ,030212 general & internal medicine ,business ,Adverse effect ,neoplasms ,Haemorrhagic enteritis ,medicine.drug - Abstract
What is known and objective 5-Azacitidine (AZA) is an agent widely used to treat myelodysplastic syndrome (MDS). Case description We herein report an 83-year-old woman diagnosed with MDS who was treated with AZA. She tolerated the first cycle of AZA; however, severe adverse events involving haemorrhagic enteritis with multiple intestinal ulcers developed after the second and third cycles. Additionally, the interval between the administration of AZA and the development of haematochezia shortened with each cycle of AZA. What is new and conclusion We herein report as-yet-undescribed potential side effects, AZA-associated haemorrhagic enteritis that should be kept in mind.
- Published
- 2020
- Full Text
- View/download PDF